DSM Biologics and UMN Pharma, Inc. have signed a biopharmaceutical manufacturing agreement based on the PER.C6 platform. Under the terms of the agreement DSM Biologics will provide UMN Pharma with full process and analytical development services and cGMP manufacturing batches for UMN’s fusion protein, UMN-03, for the treatment of muscular dystrophy and metabolic diseases. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen. The agreement follows the license agreement that was signed in March of this year between UMN Pharma, DSM Biologics and Crucell.

“The agreement builds further on the PER.C6 license agreement that is in place between UMN Pharma, DSM Biologics and Crucell. We gladly entrust DSM Biologics with the execution of this manufacturing agreement that is crucial for the success of our UMN-03 fusion protein,” said Yasunari Kashihara, president and chief executive officer of UMN Pharma.

“DSM Biologics is very happy to be involved in this exciting project. The agreement is a further example of the broad use of the PER.C6 manufacturing platform. It is also a clear recognition of the value that DSM Biologics and the PER.C6 manufacturing platform are expected to bring to UMN Pharma, an important client for DSM Biologics,” said Terry Novak, business director and chief marketing officer for DSM Biologics.